New webinar program! EDITSCD & ERN-EuroBloodNet: Explaining Genetic Therapy for People living with Sickle Cell Disease
The program starts on the 26th of September registration is open and free to all patients, families and anyone curious about the future of genetic medicine!
Gene therapy and genome editing are transforming the landscape of treatment for rare diseases and for the millions living with Sickle Cell Disease (SCD) worldwide, they hold particular promise.
To help patients, families, and the wider community better understand these emerging approaches, ERN-EuroBloodNet, in collaboration with the EDITSCD Consortium, is launching a dedicated webinar series: EDITSCD & ERN-EuroBloodNet: Focus on Genetic Therapy for People Living with SCD.
This seven-part educational program brings together leading scientists and patient advocates to explore how cutting-edge technologies like CRISPR/Cas9 and lentiviral vectors are being developed to treat SCD, from lab research to clinical trials.
Starting 26 September 2025, the webinars will run every two months until October 2026, each lasting 1 hour and featuring live AI-powered translation.
Full program & registrations: EDITSCD & ERN-EuroBloodNet Focus on Genetic Therapy for people living with SCD ' Webinars ' Patients ' Education ' EuroBloodNet
What to Expect:
- Clear, accessible explanations of the science behind gene therapy and genome editing
- Insights into safety, ethics, and regulation
- Space for interactive Q&A with top researchers
- Voices of patient representatives across Europe, shaping the conversation
The program is coordinated by the EDITSCD project led by Annarita Miccio (Imagine Institute of Genetic Diseases), with contributions from members of the steering committee and patient representatives from the European Sickle Cell Federation: Miriam Santos Freire (APPDH - Portugal), Dianaba Ba, and David Issom (Association Suisse Drépano).
Join us to stay informed, ask questions, and follow the progress of therapies that could reshape care for SCD!